Andrea Julie Bullock, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Pancreatic Ductal | 11 | 2024 | 1636 | 1.680 |
Why?
|
Pancreatic Neoplasms | 20 | 2024 | 5263 | 1.510 |
Why?
|
Adenocarcinoma | 10 | 2024 | 6364 | 0.820 |
Why?
|
Tongue Neoplasms | 1 | 2022 | 180 | 0.740 |
Why?
|
Liver Neoplasms | 7 | 2021 | 4253 | 0.720 |
Why?
|
Intestinal Pseudo-Obstruction | 1 | 2019 | 48 | 0.710 |
Why?
|
Lupus Erythematosus, Discoid | 1 | 2019 | 49 | 0.670 |
Why?
|
Budd-Chiari Syndrome | 1 | 2016 | 25 | 0.560 |
Why?
|
Leucovorin | 4 | 2022 | 628 | 0.530 |
Why?
|
Remission, Spontaneous | 1 | 2016 | 382 | 0.530 |
Why?
|
CA-19-9 Antigen | 4 | 2024 | 112 | 0.500 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2022 | 11525 | 0.480 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2016 | 153 | 0.460 |
Why?
|
Health Care Costs | 2 | 2020 | 3208 | 0.450 |
Why?
|
Fluorouracil | 4 | 2022 | 1619 | 0.430 |
Why?
|
Deoxycytidine | 6 | 2020 | 826 | 0.420 |
Why?
|
Albumins | 5 | 2021 | 568 | 0.400 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2021 | 2214 | 0.380 |
Why?
|
Mothers | 1 | 2020 | 2165 | 0.350 |
Why?
|
Esophageal Neoplasms | 1 | 2019 | 1585 | 0.350 |
Why?
|
Child Development | 1 | 2020 | 2223 | 0.330 |
Why?
|
Caregivers | 1 | 2020 | 2095 | 0.330 |
Why?
|
Public Health | 1 | 2020 | 2602 | 0.300 |
Why?
|
Paclitaxel | 5 | 2021 | 1708 | 0.290 |
Why?
|
Venous Thrombosis | 1 | 2016 | 1239 | 0.280 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4034 | 0.280 |
Why?
|
Drug Costs | 1 | 2012 | 1105 | 0.240 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2019 | 664 | 0.230 |
Why?
|
Comprehension | 2 | 2018 | 610 | 0.210 |
Why?
|
Cost of Illness | 1 | 2012 | 1860 | 0.210 |
Why?
|
Hyaluronoglucosaminidase | 2 | 2020 | 133 | 0.200 |
Why?
|
Imitative Behavior | 1 | 2020 | 33 | 0.190 |
Why?
|
Neoplasm Regression, Spontaneous | 1 | 2019 | 46 | 0.170 |
Why?
|
Decision Making | 1 | 2012 | 3888 | 0.150 |
Why?
|
Organometallic Compounds | 1 | 2021 | 665 | 0.150 |
Why?
|
Esophagogastric Junction | 1 | 2019 | 313 | 0.150 |
Why?
|
Chemokine CCL2 | 1 | 2019 | 619 | 0.140 |
Why?
|
Germ-Line Mutation | 2 | 2022 | 1788 | 0.140 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2016 | 65 | 0.140 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 567 | 0.140 |
Why?
|
Cholangiocarcinoma | 1 | 2021 | 516 | 0.140 |
Why?
|
Gallbladder Neoplasms | 1 | 2017 | 182 | 0.140 |
Why?
|
Neuroendocrine Tumors | 1 | 2021 | 594 | 0.130 |
Why?
|
alpha-Fetoproteins | 1 | 2016 | 224 | 0.130 |
Why?
|
Middle Aged | 25 | 2021 | 213390 | 0.130 |
Why?
|
Cholecystectomy | 1 | 2017 | 395 | 0.130 |
Why?
|
BRCA1 Protein | 1 | 2022 | 1149 | 0.130 |
Why?
|
Internet | 2 | 2018 | 3056 | 0.130 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4262 | 0.130 |
Why?
|
Female | 28 | 2022 | 380193 | 0.130 |
Why?
|
Ultrasonography | 2 | 2019 | 5984 | 0.120 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 2 | 2015 | 437 | 0.120 |
Why?
|
Enoxaparin | 2 | 2017 | 377 | 0.120 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2924 | 0.120 |
Why?
|
Aged | 22 | 2021 | 163288 | 0.120 |
Why?
|
Proto-Oncogene Proteins | 2 | 2018 | 4554 | 0.120 |
Why?
|
Kidney Cortex Necrosis | 1 | 2013 | 6 | 0.120 |
Why?
|
Cholecalciferol | 1 | 2019 | 535 | 0.120 |
Why?
|
Consumer Health Information | 1 | 2016 | 211 | 0.120 |
Why?
|
STAT3 Transcription Factor | 1 | 2018 | 874 | 0.120 |
Why?
|
Life Expectancy | 1 | 2020 | 1184 | 0.120 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 720 | 0.110 |
Why?
|
Neoplasms | 4 | 2020 | 21696 | 0.110 |
Why?
|
Nephrectomy | 1 | 2019 | 1050 | 0.110 |
Why?
|
Humans | 40 | 2024 | 744366 | 0.110 |
Why?
|
Portal Vein | 1 | 2016 | 437 | 0.110 |
Why?
|
Male | 27 | 2023 | 350115 | 0.110 |
Why?
|
Vena Cava, Inferior | 1 | 2016 | 440 | 0.110 |
Why?
|
Sphingosine | 1 | 2015 | 307 | 0.110 |
Why?
|
Patient Education as Topic | 2 | 2020 | 2278 | 0.110 |
Why?
|
Lysophospholipids | 1 | 2015 | 331 | 0.110 |
Why?
|
Aged, 80 and over | 10 | 2021 | 57776 | 0.100 |
Why?
|
Carcinoma, Renal Cell | 2 | 2019 | 3143 | 0.100 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13104 | 0.100 |
Why?
|
Lymph Node Excision | 1 | 2017 | 1262 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2016 | 1851 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5534 | 0.100 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4851 | 0.100 |
Why?
|
Thromboplastin | 1 | 2012 | 291 | 0.100 |
Why?
|
Serine Endopeptidases | 1 | 2016 | 1073 | 0.090 |
Why?
|
Thromboembolism | 2 | 2017 | 987 | 0.090 |
Why?
|
Embolization, Therapeutic | 1 | 2020 | 1392 | 0.090 |
Why?
|
Vitamins | 1 | 2019 | 1623 | 0.090 |
Why?
|
Yttrium Radioisotopes | 2 | 2021 | 93 | 0.090 |
Why?
|
Colorectal Neoplasms | 2 | 2020 | 6773 | 0.090 |
Why?
|
Ambulatory Care | 1 | 2020 | 2708 | 0.080 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2011 | 358 | 0.080 |
Why?
|
Early Detection of Cancer | 2 | 2020 | 3086 | 0.080 |
Why?
|
Palliative Care | 2 | 2020 | 3493 | 0.080 |
Why?
|
Microspheres | 2 | 2021 | 777 | 0.080 |
Why?
|
Catheter Ablation | 1 | 2021 | 2758 | 0.080 |
Why?
|
Hepatitis C, Chronic | 1 | 2016 | 1031 | 0.080 |
Why?
|
Pilot Projects | 1 | 2020 | 8319 | 0.070 |
Why?
|
Pancreas | 2 | 2024 | 1687 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2019 | 3296 | 0.070 |
Why?
|
Lymph Nodes | 1 | 2017 | 3476 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3707 | 0.070 |
Why?
|
Hyaluronic Acid | 2 | 2020 | 491 | 0.070 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2006 | 215 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5253 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 13693 | 0.060 |
Why?
|
Carbolines | 1 | 2006 | 265 | 0.060 |
Why?
|
Prognosis | 6 | 2020 | 29060 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2019 | 6896 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39052 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2013 | 2949 | 0.060 |
Why?
|
Pancreatectomy | 2 | 2018 | 804 | 0.050 |
Why?
|
Retrospective Studies | 6 | 2021 | 77460 | 0.050 |
Why?
|
Erectile Dysfunction | 1 | 2006 | 461 | 0.050 |
Why?
|
Antibodies, Monoclonal | 2 | 2019 | 9274 | 0.050 |
Why?
|
Radiosurgery | 1 | 2011 | 1329 | 0.050 |
Why?
|
Cytidine | 1 | 2021 | 68 | 0.050 |
Why?
|
Metabolic Clearance Rate | 1 | 2021 | 380 | 0.050 |
Why?
|
Gallium Radioisotopes | 1 | 2021 | 178 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10259 | 0.050 |
Why?
|
Cohort Studies | 2 | 2020 | 40559 | 0.050 |
Why?
|
Half-Life | 1 | 2021 | 661 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2020 | 25628 | 0.050 |
Why?
|
Liver | 1 | 2016 | 7475 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 35425 | 0.050 |
Why?
|
Multimedia | 1 | 2020 | 77 | 0.050 |
Why?
|
Medical Oncology | 1 | 2012 | 2267 | 0.050 |
Why?
|
Spasm | 1 | 2020 | 121 | 0.050 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 295 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2019 | 3480 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2015 | 5172 | 0.040 |
Why?
|
Insurance, Health | 1 | 2012 | 2494 | 0.040 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2002 | 366 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2017 | 9240 | 0.040 |
Why?
|
Niacinamide | 1 | 2021 | 416 | 0.040 |
Why?
|
Receptor, Notch2 | 1 | 2019 | 89 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 892 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2016 | 7882 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4933 | 0.040 |
Why?
|
Acetaminophen | 1 | 2002 | 545 | 0.040 |
Why?
|
Infant | 1 | 2020 | 35134 | 0.040 |
Why?
|
Medicaid | 1 | 2012 | 2737 | 0.040 |
Why?
|
Adult | 11 | 2020 | 214052 | 0.040 |
Why?
|
Physician-Patient Relations | 1 | 2012 | 3229 | 0.040 |
Why?
|
Chemokine CXCL10 | 1 | 2019 | 305 | 0.040 |
Why?
|
Phenylurea Compounds | 1 | 2021 | 528 | 0.040 |
Why?
|
Child, Preschool | 1 | 2020 | 41005 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2021 | 10943 | 0.040 |
Why?
|
Pancreatitis, Chronic | 1 | 2020 | 285 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6539 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11031 | 0.040 |
Why?
|
Anticoagulants | 1 | 2012 | 4600 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2021 | 2031 | 0.040 |
Why?
|
Hyponatremia | 1 | 2020 | 298 | 0.040 |
Why?
|
Lung | 1 | 2016 | 9857 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 342 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2012 | 3922 | 0.040 |
Why?
|
Area Under Curve | 1 | 2021 | 1655 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2018 | 408 | 0.040 |
Why?
|
Pancreatic Cyst | 1 | 2020 | 368 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17446 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2018 | 8432 | 0.030 |
Why?
|
Disease Progression | 3 | 2020 | 13286 | 0.030 |
Why?
|
Organizations, Nonprofit | 1 | 2016 | 104 | 0.030 |
Why?
|
Organoids | 1 | 2022 | 701 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 547 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2018 | 3595 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2020 | 12025 | 0.030 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2017 | 230 | 0.030 |
Why?
|
Death | 1 | 2020 | 678 | 0.030 |
Why?
|
Government | 1 | 2016 | 165 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 841 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 552 | 0.030 |
Why?
|
Metabolomics | 1 | 2023 | 1485 | 0.030 |
Why?
|
Survival Rate | 2 | 2020 | 12788 | 0.030 |
Why?
|
Pancreaticoduodenectomy | 1 | 2017 | 503 | 0.030 |
Why?
|
Medicare | 1 | 2012 | 6566 | 0.030 |
Why?
|
Treatment Outcome | 5 | 2021 | 63107 | 0.030 |
Why?
|
Ownership | 1 | 2016 | 332 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12356 | 0.030 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2018 | 594 | 0.030 |
Why?
|
United States | 4 | 2020 | 69872 | 0.030 |
Why?
|
Renal Veins | 1 | 2013 | 108 | 0.030 |
Why?
|
Mass Media | 1 | 2016 | 305 | 0.030 |
Why?
|
Mutation | 1 | 2018 | 29786 | 0.030 |
Why?
|
Genes, Lethal | 1 | 2013 | 242 | 0.030 |
Why?
|
Cell Respiration | 1 | 2013 | 201 | 0.030 |
Why?
|
Fatigue | 1 | 2020 | 1531 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1928 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20130 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2017 | 973 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 2282 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10252 | 0.030 |
Why?
|
Incidental Findings | 1 | 2017 | 689 | 0.030 |
Why?
|
Complementary Therapies | 1 | 2016 | 486 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2017 | 1771 | 0.030 |
Why?
|
Heart Failure | 1 | 2016 | 10895 | 0.030 |
Why?
|
Cell-Derived Microparticles | 1 | 2012 | 168 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5077 | 0.020 |
Why?
|
Propensity Score | 1 | 2017 | 1781 | 0.020 |
Why?
|
Aspirin | 1 | 2002 | 3283 | 0.020 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2012 | 426 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2727 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2018 | 10483 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2018 | 9445 | 0.020 |
Why?
|
Carcinoma in Situ | 1 | 2016 | 806 | 0.020 |
Why?
|
DNA Methylation | 1 | 2024 | 4285 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 2086 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2133 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4185 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1915 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2013 | 1656 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2460 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2019 | 3511 | 0.020 |
Why?
|
Information Dissemination | 1 | 2016 | 1099 | 0.020 |
Why?
|
Fibrinolytic Agents | 1 | 2017 | 2158 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2725 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2715 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2015 | 16690 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2013 | 1701 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 53290 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3590 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3554 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2015 | 1707 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2013 | 20824 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2076 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2760 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2021 | 6234 | 0.020 |
Why?
|
Coitus | 1 | 2006 | 133 | 0.020 |
Why?
|
Young Adult | 1 | 2012 | 56429 | 0.020 |
Why?
|
Up-Regulation | 1 | 2015 | 4222 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14723 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 12961 | 0.020 |
Why?
|
Vitamin D | 1 | 2019 | 3224 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12244 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 2988 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2011 | 2879 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2638 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11366 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 9955 | 0.010 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 1624 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 7023 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 7914 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18373 | 0.010 |
Why?
|
Thrombosis | 1 | 2013 | 2968 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2011 | 8642 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 23336 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2016 | 21748 | 0.010 |
Why?
|
Mice | 2 | 2015 | 81201 | 0.010 |
Why?
|
Drug Utilization | 1 | 2002 | 1183 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 40075 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18034 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2006 | 3395 | 0.010 |
Why?
|
Animals | 2 | 2015 | 168768 | 0.010 |
Why?
|
Signal Transduction | 1 | 2013 | 23404 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2002 | 25039 | 0.000 |
Why?
|